First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial

ANNALS OF ONCOLOGY

ELSEVIER

1. French Academic Projet Hospitalier Recherche Clinique (PHRC)
2. AAA/Novartis Pharma